JP4628675B2 - 可溶化トポイソメラーゼ毒 - Google Patents

可溶化トポイソメラーゼ毒 Download PDF

Info

Publication number
JP4628675B2
JP4628675B2 JP2003543547A JP2003543547A JP4628675B2 JP 4628675 B2 JP4628675 B2 JP 4628675B2 JP 2003543547 A JP2003543547 A JP 2003543547A JP 2003543547 A JP2003543547 A JP 2003543547A JP 4628675 B2 JP4628675 B2 JP 4628675B2
Authority
JP
Japan
Prior art keywords
compound
mmol
alkyl
prepared
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003543547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511617A5 (US07049315-20060523-C00010.png
JP2005511617A (ja
Inventor
エドモンド ジェイ． ラボイー，
アレキサンダー エル． ラチェルマン，
ラロイ エフ． リウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of JP2005511617A publication Critical patent/JP2005511617A/ja
Publication of JP2005511617A5 publication Critical patent/JP2005511617A5/ja
Application granted granted Critical
Publication of JP4628675B2 publication Critical patent/JP4628675B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
JP2003543547A 2001-11-14 2002-11-14 可溶化トポイソメラーゼ毒 Expired - Fee Related JP4628675B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33273401P 2001-11-14 2001-11-14
PCT/US2002/036901 WO2003041660A2 (en) 2001-11-14 2002-11-14 Solubilized topoisomerase poisons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010126977A Division JP5337104B2 (ja) 2001-11-14 2010-06-02 可溶化トポイソメラーゼ毒

Publications (3)

Publication Number Publication Date
JP2005511617A JP2005511617A (ja) 2005-04-28
JP2005511617A5 JP2005511617A5 (US07049315-20060523-C00010.png) 2006-01-19
JP4628675B2 true JP4628675B2 (ja) 2011-02-09

Family

ID=23299632

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003543547A Expired - Fee Related JP4628675B2 (ja) 2001-11-14 2002-11-14 可溶化トポイソメラーゼ毒
JP2010126977A Expired - Fee Related JP5337104B2 (ja) 2001-11-14 2010-06-02 可溶化トポイソメラーゼ毒
JP2013120501A Pending JP2013166801A (ja) 2001-11-14 2013-06-07 可溶化トポイソメラーゼ毒

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010126977A Expired - Fee Related JP5337104B2 (ja) 2001-11-14 2010-06-02 可溶化トポイソメラーゼ毒
JP2013120501A Pending JP2013166801A (ja) 2001-11-14 2013-06-07 可溶化トポイソメラーゼ毒

Country Status (15)

Country Link
US (4) US7049315B2 (US07049315-20060523-C00010.png)
EP (3) EP1465625B1 (US07049315-20060523-C00010.png)
JP (3) JP4628675B2 (US07049315-20060523-C00010.png)
KR (1) KR20050044491A (US07049315-20060523-C00010.png)
AT (1) ATE456952T1 (US07049315-20060523-C00010.png)
AU (1) AU2002363658B2 (US07049315-20060523-C00010.png)
CA (1) CA2467774C (US07049315-20060523-C00010.png)
CY (1) CY1110631T1 (US07049315-20060523-C00010.png)
DE (1) DE60235287D1 (US07049315-20060523-C00010.png)
DK (1) DK1465625T3 (US07049315-20060523-C00010.png)
ES (1) ES2340473T3 (US07049315-20060523-C00010.png)
MX (1) MXPA04004606A (US07049315-20060523-C00010.png)
PT (1) PT1465625E (US07049315-20060523-C00010.png)
SI (1) SI1465625T1 (US07049315-20060523-C00010.png)
WO (1) WO2003041660A2 (US07049315-20060523-C00010.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047505A2 (en) 2001-11-14 2003-06-12 Rutgers, The State University Topoisomerase poison agents
CA2467279A1 (en) 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
SI1465625T1 (sl) 2001-11-14 2010-06-30 Univ Rutgers Solubilizirani topoizomerazni strupi
EP1453812B1 (en) 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
WO2004014906A2 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003265406A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
CA2510337C (en) 2002-11-12 2013-01-08 Rutgers, The State University Of New Jersey Topoisomerase-targeting agents
US7652029B2 (en) 2004-07-09 2010-01-26 Medisyn Technologies, Inc. Therapeutic compound and treatments
WO2007140248A1 (en) * 2006-05-24 2007-12-06 Dr. Reddy's Laboratories Limited 5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin and its preparation and use for the treatment of cancer
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
TW201038578A (en) * 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
WO2010127360A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2012015875A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating hematological malignancies
WO2012015901A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating gastric and pancreatic malignancies
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
CN109219610A (zh) 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
CN111925370B (zh) * 2020-09-01 2023-07-21 湖北科苑生物药业有限公司 一种吡嗪并吡唑并萘啶类化合物及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) * 1961-04-25 Acridine derivatives
US2985681A (en) * 1953-08-28 1961-05-23 Knoll Ag Phenylacetic acid and aminoalkyl esters thereof
US2985661A (en) * 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) * 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) * 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420044A (de) * 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Azol-Derivaten als optische Aufheller für textile organische Materialien
US3267107A (en) * 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) * 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) * 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (US07049315-20060523-C00010.png) * 1972-08-25 1974-04-22
US3912740A (en) * 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US4749708A (en) * 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US5153178A (en) * 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US4980344A (en) * 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) * 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd １３−プロピルベルベリンの塩
FR2595356B1 (fr) * 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) * 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
DE4116593C1 (US07049315-20060523-C00010.png) * 1991-05-22 1993-01-07 Fa. Hermann Heye, 3063 Obernkirchen, De
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
CA2150235A1 (en) 1993-09-28 1995-04-06 Fumio Suzuki A novel tetracyclic compound
US5767142A (en) * 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5807874A (en) * 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
HUP9900071A3 (en) 1995-05-17 2002-01-28 Univ Rutgers Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
HUP9900413A3 (en) 1996-02-12 2002-02-28 Univ Rutgers Use of coralyne derivatives, new coralyne derivatives and use thereof, pharmaceutical compositions containing these new coralyne derivatives
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
PL332416A1 (en) 1996-09-23 1999-09-13 Rutgers Substituted heterocyclic compounds as anticarcinogenic agents
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU765135B2 (en) * 1998-10-14 2003-09-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel indenoisoquinolines as antineoplastic agents
JP2003513079A (ja) * 1999-10-29 2003-04-08 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 複素環式細胞傷害剤
US6740650B2 (en) * 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
CN1612723A (zh) 2001-11-13 2005-05-04 宝洁公司 包含由抑制剂稳定化的酶的局部组合物
EP1453812B1 (en) * 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
SI1465625T1 (sl) 2001-11-14 2010-06-30 Univ Rutgers Solubilizirani topoizomerazni strupi
WO2003047505A2 (en) * 2001-11-14 2003-06-12 Rutgers, The State University Topoisomerase poison agents
CA2467279A1 (en) * 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
US6970985B2 (en) * 2002-07-09 2005-11-29 Bluerisc Inc. Statically speculative memory accessing
WO2004014906A2 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) * 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003265406A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
CA2510337C (en) * 2002-11-12 2013-01-08 Rutgers, The State University Of New Jersey Topoisomerase-targeting agents

Also Published As

Publication number Publication date
US20050009824A1 (en) 2005-01-13
US20060052381A1 (en) 2006-03-09
EP2196205A1 (en) 2010-06-16
WO2003041660A2 (en) 2003-05-22
KR20050044491A (ko) 2005-05-12
US20110136812A1 (en) 2011-06-09
US20090239871A1 (en) 2009-09-24
US7049315B2 (en) 2006-05-23
CY1110631T1 (el) 2015-04-29
MXPA04004606A (es) 2004-09-10
SI1465625T1 (sl) 2010-06-30
DE60235287D1 (de) 2010-03-25
ATE456952T1 (de) 2010-02-15
JP5337104B2 (ja) 2013-11-06
JP2010184942A (ja) 2010-08-26
EP1465625A4 (en) 2005-06-08
PT1465625E (pt) 2010-03-09
CA2467774A1 (en) 2003-05-22
AU2002363658B2 (en) 2008-09-11
CA2467774C (en) 2011-09-20
JP2005511617A (ja) 2005-04-28
EP1465625A2 (en) 2004-10-13
US8389721B2 (en) 2013-03-05
ES2340473T3 (es) 2010-06-04
EP2286812A1 (en) 2011-02-23
JP2013166801A (ja) 2013-08-29
DK1465625T3 (da) 2010-05-31
US7781587B2 (en) 2010-08-24
EP1465625B1 (en) 2010-02-03
US7517883B2 (en) 2009-04-14
WO2003041660A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
JP5337104B2 (ja) 可溶化トポイソメラーゼ毒
US7468366B2 (en) Cytotoxic agents
US20100240664A1 (en) Solubilized topoisomerase poison agents
AU2002363658A1 (en) Solubilized topoisomerase poisons
JP2006512319A (ja) トポイソメラーゼ−ターゲッティング剤
US20120004235A1 (en) Methods to treat cancer
WO2012015875A1 (en) Methods for treating hematological malignancies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100824

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101013

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101110

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131119

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4628675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees